Thus, antibody-based radiotherapies and recent progress in immunotherapies seem to the most promising therapeutic approaches for PCa, in particular PROVENGE (Sipuleucel-T) and PROSTVAC involving PSA as the target of vaccination, which both reached phase three clinical trials [177]. The gene discussed is KLK3; the disease is posterior cortical atrophy.